CD52 and acute lymphoblastic leukemia: The B-ALL studies either applied a TRAC plus CD52 [218, 220, 221, 223, 225, 226, 231] or an IL-6 KO/KD [217, 219, 222, 224, 227–230, 232] strategy, using anti-CD19 [217, 219–224, 226–232] or anti-CD22 [218, 223, 225, 230], and all reached promising results.